Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) SEC filings page aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing structured access to the regulatory record behind its transformation and financing activities. These documents include current reports on Form 8‑K, registration statements on Form S‑1, and proxy materials on Schedule 14A, among others.
For this issuer, Form 8‑K filings are particularly important. They detail key events such as the completion of the strategic merger with Decoy Therapeutics, the issuance of Series A and Series B Non‑Voting Convertible Preferred Stock, underwritten public offerings of common stock and warrants, reverse stock split implementation, Nasdaq listing compliance updates and notices related to minimum bid price and equity standards. One 8‑K filed in early 2026 describes a Nasdaq notice regarding non-compliance with the minimum bid price requirement and the company’s stated intention to appeal a delisting determination to a Nasdaq Hearings Panel.
Registration statements on Form S‑1 and their amendments outline the terms of public offerings, including the number of shares, pre-funded warrants, Series A and Series B warrants and representative warrants, as well as intended use of proceeds such as advancing research and development programs and addressing Decoy promissory notes. The DEF 14A definitive proxy statement provides insight into corporate governance, board elections, executive compensation proposals and the conduct of the 2025 Annual Meeting of Stockholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain complex structures in accessible language, highlighting elements such as the preferred stock conversion mechanics tied to the Decoy merger, conditions for Nasdaq initial listing standards, and the implications of reverse stock splits and listing notices. Users can quickly locate quarterly and annual reports when available, review historical and current 8‑Ks, and examine equity and warrant terms without reading every page of the original documents.
Because insider transaction information for SLRX, when filed on Form 4 or related ownership forms, also appears in the SEC’s EDGAR system, this page serves as a starting point for tracking changes in beneficial ownership alongside the broader corporate actions disclosed by Salarius and its successor branding as Decoy Therapeutics.
Decoy Therapeutics Inc. files its annual report describing a preclinical-stage biotechnology business built around the AI- and machine-learning–enabled IMP3ACT™ peptide conjugate platform. The company is developing Designable Multi-Antivirals targeting conserved viral fusion mechanisms, led by a nasally inhaled pan-coronavirus prophylactic for immunocompromised patients and a planned broad respiratory antiviral for flu, COVID-19, and RSV.
The report details the November 2025 merger with Legacy Decoy, a subsequent name and ticker change, and two reverse stock splits (1-for-15 in 2025 and 1-for-12 in 2026) used alongside capital raises to maintain Nasdaq listing compliance. Management highlights substantial doubt about the company’s ability to continue as a going concern, ongoing operating losses, reliance on future financings and non‑dilutive grants, and early-stage programs that have not yet generated product revenue.
Decoy Therapeutics Inc. is implementing a 1-for-12 reverse stock split of its common stock to help regain compliance with Nasdaq’s minimum $1.00 bid price requirement. The split becomes effective at 5:00 p.m. Eastern Time on March 6, 2026.
Every 12 issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 6.38 million shares to approximately 532,000 shares, while authorized common shares remain at 100 million and par value stays $0.0001 per share. Trading on a split-adjusted basis on the Nasdaq Capital Market under the symbol DCOY and new CUSIP 79400X602 is expected to begin March 9, 2026.
All outstanding options, warrants, restricted stock units and shares reserved under equity plans will be adjusted proportionately. Fractional shares will be rounded down and paid in cash based on the March 6, 2026 closing price.
Decoy Therapeutics Inc. reported that stockholders approved all matters presented at a virtual special meeting held on February 24, 2026. The meeting had a quorum with 2,696,758 common shares represented. Stockholders approved the 2026 Equity Incentive Plan, providing a new framework for equity-based compensation.
They also approved a reverse stock split of outstanding common stock at a ratio between 1-for-4 and 1-for-15, with the exact ratio to be set at the board’s discretion. An adjournment proposal was approved as well, but the meeting did not need to be adjourned because sufficient votes were obtained for the main proposals.
Decoy Therapeutics Inc. investor reports a 9.9% passive stake. CVI Investments, Inc. and Heights Capital Management, Inc. jointly report beneficial ownership of 708,565 shares of Decoy Therapeutics common stock, all issuable upon exercise of warrants.
Their ownership represents 9.9% of the common stock, based on 6,384,177 shares outstanding as of December 26, 2025, as cited from the company’s definitive proxy statement. The warrants are subject to a 9.99% beneficial ownership cap, limiting exercise if it would push total holdings above that level. The filers certify the securities were not acquired to change or influence control of the company.
Salarius Pharmaceuticals reports that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule because the closing bid for its common stock was below $1.00 per share for the last 30 consecutive business days. Due to a prior reverse stock split within the last year and the company’s status under a Mandatory Panel Monitor, Salarius is not eligible for the standard 180‑day grace period normally allowed to regain compliance.
Nasdaq has determined that the company’s securities will be scheduled for delisting from The Nasdaq Capital Market and suspended at the opening of business on January 9, 2026, with a Form 25‑NSE to remove them from listing and registration, unless Salarius appeals by January 7, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel and present plans to regain compliance, but it states there is no assurance of a favorable outcome or that its securities will remain listed.
Salarius Pharmaceuticals, Inc. (SLRX) director reports stock purchase. A trust associated with director Arnold C. Hanish bought 5,000 shares of Salarius common stock on 11/20/2025 at a weighted average price of $0.7481 per share. These shares were acquired in multiple trades at prices ranging from $0.7437 to $0.75. After this transaction, the trust beneficially owned 5,015 shares of Salarius common stock, reported as indirect ownership on the Form 4.
Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 reporting the equity holdings of its Chief Business Officer. The filing shows derivative securities rather than direct common stock ownership. The officer holds stock options to buy 5,061 shares of common stock at an exercise price of $4.9369 per share, expiring on 03/31/2032, and options to buy 8,318 shares at $50.2579 per share, expiring on 07/15/2030. The officer also holds Series A Preferred Shares that are convertible into common stock after stockholder approval and satisfaction of specified Nasdaq listing standards, and the preferred shares have no expiration date.
Salarius Pharmaceuticals, Inc. (SLRX) filed an initial Form 3 for its Chief Scientific Officer, reporting only derivative securities. The reporting person holds Series A Preferred Stock that is convertible into 141,734 shares of common stock. The Series A Preferred has no expiration date and will convert automatically into common shares after stockholder approval and satisfaction of specified Nasdaq listing standards.
The filing also reports two stock options for common stock: one covering 5,061 shares with an exercise price of $4.9369 per share and another covering 8,318 shares with an exercise price of $50.2579 per share. Both option grants become exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards, so their potential value depends on these conditions being met.
Salarius Pharmaceuticals (SLRX) disclosed the equity holdings of its Chief Executive Officer in connection with an event dated 11/12/2025. The CEO beneficially owns 16,666 shares of common stock directly. In addition, he holds Series A Preferred Stock that is convertible into 141,734 shares of common stock, which will automatically convert after stockholder approval and satisfaction of certain Nasdaq listing standards.
The CEO also holds derivative securities, including Series A and Series B warrants each exercisable for 16,666 shares of common stock at an exercise price of $1.5, with expiration dates on 11/12/2030 and 11/12/2026, respectively. He further holds stock options for 5,061 and 8,318 shares of common stock at exercise prices of $4.9369 and $50.2579, with some options exercisable only after stockholder approval and satisfaction of certain Nasdaq listing standards.
Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum. On 11/20/2025, he bought 20,000 shares of Salarius common stock at a price of $0.80 per share in an open-market transaction. After this purchase, he beneficially owns 20,177 shares of common stock, which includes 20 shares of unvested restricted stock granted on January 3, 2023. The reported post-transaction share amount reflects prior reverse stock splits that were effective on June 16, 2024 and August 17, 2025.